Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.71 |
| ▸ | CNR2 | P34972 | 4/20 | 0.68 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12884556 | 1.00 | CNR1 (0.71) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL12884874 | 0.90 | CNR1 (0.66) | CNR1CNR2PTGER4 | |
| SCHEMBL12884869 | 0.87 | CNR1 (0.67) | CNR1CNR2PTGER4MEN1KMT2A | |
| SCHEMBL25368006 | 0.87 | CNR1 (0.72) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL1217138 | 0.85 | CNR1 (0.72) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL27823781 | 0.85 | CNR1 (0.72) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL12884886 | 0.83 | CNR1 (0.67) | CNR1CNR2PTGER4KMT2A | |
| SCHEMBL29362171 | 0.83 | CNR1 (1.00) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL1217062 | 0.83 | CNR1 (1.00) | CNR1CNR2PTGER4PTGS1PTGS2 | |
| SCHEMBL16201827 | 0.83 | CNR1 (1.00) | CNR1CNR2PTGER4PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | PASCAL BIOSCIENCES INC (CA) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270763-A1 | METHOD OF TREATING CORONOVIRUS INFECTIONS WITH CANNABINOIDS AND DERIVATIVES | CNR1, CNR2, SARS1 | CNR1 1/4885CNR2 2/4885PTGER4 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.